Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.67 |
| ▸ | DRD3 | P35462 | 12/20 | 0.67 |
| ▸ | DRD4 | P21917 | 6/20 | 0.67 |
| ▸ | DRD2 | P14416 | 10/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27553852 | 0.98 | OPRM1 (0.65) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL10440077 | 0.85 | OPRM1 (0.73) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL6309263 | 0.83 | OPRM1 (0.65) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL10884718 | 0.83 | OPRM1 (0.65) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL6078982 | 0.83 | CHRM2 (0.53) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL7173871 | 0.81 | OPRM1 (0.73) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL24683657 | 0.80 | OPRM1 (0.61) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL20245629 | 0.80 | OPRM1 (0.71) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL5038143 | 0.80 | OPRM1 (0.65) | OPRM1DRD3DRD4DRD2CHRM2 | |
| SCHEMBL11752498 | 0.79 | CHRM2 (0.51) | OPRM1DRD3DRD4DRD2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015184317-A1 | PHARMACEUTICAL COMPOSITION WITH IONICALLY CROSSLINKED POLYMER ENCAPSULATION OF ACTIVE INGREDIENT | ALLEN ERIC (US) | 2015-12-03 | — | — | WO | claimed |
| US-20260027068-A1 | METHODS OF ADMINISTERING R-KETAMINE | PERCEPTION NEUROSCIENCE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4313039-B1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | MOLECULAR RES PHARMACT S R L (IT) | 2025-09-03 | — | — | EP | disclosed |
| US-20240197699-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | MOLECULAR RESEARCH PHARMACT S.R.L. (IT) | 2024-06-20 | — | — | US | disclosed |
| EP-4313039-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | Molecular Research Pharmact S.r.l. (IT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208375-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | MOLECULAR RESEARCH PHARMACT S.R.L. (IT) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022187206-A1 | DUAL-TARGET MU OPIOID AND DOPAMINE D3 RECEPTORS LIGANDS; PREPARATION AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11426367-B2 | Methods of treating substance abuse | PERCEPTION NEUROSCIENCE, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2015184317-A1 | PHARMACEUTICAL COMPOSITION WITH IONICALLY CROSSLINKED POLYMER ENCAPSULATION OF ACTIVE INGREDIENT | ALLEN ERIC (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2014178065-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-11-06 | — | — | WO | disclosed |
| US-8716657-B2 | High sensitivity mass spectrometry systems | ILLINOIS STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140042313-A1 | HIGH SENSITIVITY MASS SPECTROMETRY SYSTEMS | ILLINOIS STATE UNIVERSITY (US) | 2014-02-13 | — | — | US | disclosed |
| US-8592754-B2 | High sensitivity mass spectrometry systems | ILLINOIS STATE UNIVERSITY (US) | 2013-11-26 | — | — | US | disclosed |
| WO-2012155090-A2 | HIGH SENSITIVITY MASS SPECTROMETRY SYSTEMS | ILLINOIS STATE UNIVERSITY (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120286155-A1 | High Sensitivity Mass Spectrometry Systems | ILLINOIS STATE UNIVERSITY (US) | 2012-11-15 | — | — | US | disclosed |
| EP-1709029-A2 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2006-10-11 | — | — | EP | disclosed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| WO-2005075455-A2 | METHODS FOR MAKING 4-TETRAZOLYL-4-PHENYLPIPERIDINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2005-08-18 | — | — | WO | disclosed |
| CN-1469862-A | 2, 2-diphenylbutanamide derivatives and drugs containing the same | SS制药株式会社 | 2004-01-21 | — | — | CN | disclosed |
| CN-1304929-A | 4-hydroxy-4-phenyl piperidine derivative and medicine containing said derivative | SS PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197699-A1 | BENZOMORPHAN DERIVATE FOR USE IN THERAPY | FABP4, ADIPOR1, GPR119 | OPRM1 6/4885DRD3 933/4885DRD4 456/4885 |
| US-11426367-B2 | Methods of treating substance abuse | OPRK1, TACR2, SLC6A3 | OPRM1 12/4885DRD3 38/4885DRD4 60/4885 |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | OPRM1 72/4885DRD3 369/4885DRD4 290/4885 |
| US-20260027068-A1 | METHODS OF ADMINISTERING R-KETAMINE | SNCA, OPRD1, OPRK1 | OPRM1 22/4885DRD3 21/4885DRD4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.